Holen Sie sich die Stockscreener-App
0.7891
1.17%
-0.000100
Mira Pharmaceuticals Inc Aktie (MIRA) Neueste Nachrichten
Nearly 300 flights are cancelled due to problems in UK air traffic control system, flight monitor Flightradar24 reports - barchart.com
This Under-the-Radar Biopharma Is Moving MIRA-55, a Non-Opioid Pain Drug That Outperformed Morphine Closer to the Clinic - Barchart.com
Mira advances IND-enabling studies of MIRA-55 for pain - BioWorld News
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? - Benzinga
MIRA Pharmaceuticals reports toxicology data for pain drug candidate By Investing.com - Investing.com South Africa
MIRA-55 toxicology results advance non-opioid pain program - TipRanks
MIRA Pharmaceuticals reports toxicology data for pain drug candidate - Investing.com
MIRA Pharmaceuticals Advances Non-Opioid Oral MIRA-55 for Inflammatory Pain Toward IND - GlobeNewswire
MIRA (MIRA) Update: Holds Near $0.73 on the Day; Key Range: $0.69 and $0.77 Define the Nearby Reference Levels for the Current SessionInitial Balance - vinanet.vn
MIRA (MIRA) Financial Results: The Company Lists Its Latest Available Figures in the Latest Session; Investor Response: Shares Fall 3.16% in the Latest ReadingSegment Revenue Breakdown - vinanet.vn
MIRA Q2 2026 Earnings: -$0.03 EPS Reinforces Clinical-Stage, Pre-Revenue StatusBanking Earnings Report - vinanet.vn
MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire
MIRA Pharmaceuticals (MIRA) Earnings Date and Reports 2026 - MarketBeat
MIRA Pharmaceuticals Edges Higher: Stock Gains 1.37% as Shares Hold Key Support LevelCup and Handle - dars.gov.et
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss of -$0.06 Per Share Highlights Cost DisciplineUpward Estimate Revision - vinanet.vn
Mira Pharmaceuticals Inc (MIRA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives 9.36% Stock GainSegment Revenue Breakdown - vinanet.vn
Form 8K Mira Pharmaceuticals Inc For: 6 August By Investing.com - Investing.com South Africa
MIRA's obesity candidate shows rapid absorption in 7-day dog study - stocktitan.net
MIRA Reports Positive 7-Day Dog Study Results for SKNY-1 - Asianet Newsable
MIRA Reports Positive Preclinical Results for Obesity Candidate SKNY-1 - TipRanks
NAGE Stock Price and Chart — NASDAQ:NAGE - TradingView
12 Health Care Stocks Moving In Monday's After-Market SessionEnsysce Biosciences (NASDAQ:ENSC), TransC - Benzinga
MIRA Q3 2025 Earnings: Narrower-Than-Expected Loss Highlights Cost Discipline in Pre-Revenue Stage - vinanet.vn
MIRA Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:MIRA - TradingView
MIRA Pharmaceuticals Receives Nasdaq Minimum Bid Price Notice - TipRanks
Mira advances MIRA-55 and SKNY-1 - bioworld.com
Mira Pharmaceuticals Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
MIRA Pharmaceuticals Progresses MIRA-55 and SKNY-1 Toward IND-Enabling Studies - GlobeNewswire
MIRA Q3 2025 Earnings: EPS Beat on Narrower Loss Highlights Cost DisciplinePost-Announcement Reaction - vinanet.vn
MIRA Q3 2025 Earnings: Narrower-than-Expected Loss Drives Positive Surprise Despite Stock DeclineEBITDA Margin Trends - vinanet.vn
Mira Pharmaceuticals Inc (MIRA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Mira Pharmaceuticals Inc (MIRA) Cash Flow - TradingKey
Mira Pharmaceuticals Inc (MIRA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Telomir Pharmaceuticals Inc (TELO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Mira Pharmaceuticals Inc (MIRA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Mira Pharmaceuticals Inc (MIRA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MIRA Q3 2025 Earnings: EPS Surprise of 26.47% on Narrowed Loss Despite No RevenueEarnings Miss Alert - vinanet.vn
MIRA|Mira Pharmaceuticals Inc|Price:0.764|Chg%:-0.025 - TradingKey
Mira Pharmaceuticals Inc (MIRA) Income Statement - TradingKey
TradingKey - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – DUS:K6S - TradingView
MIRA|Mira Pharmaceuticals Inc|Price:0.882|Chg%:+0.000 - TradingKey
MIRA Pharmaceuticals, Inc. Revenue Breakdown – LSX:A3EQWL - TradingView
Mira Pharmaceuticals Inc (MIRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
MIRA Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:MIRA) - TradingView
Mergers & Acquisitions - Modern Healthcare
MIRA Q3 2025 Earnings: Narrower-than-expected Loss Amid Pre-Revenue PhaseConsensus Miss Rate - vinanet.vn
Andriy Mushak Net Worth (2026) - GuruFocus
Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media
MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire
MIRA Q3 2025 Earnings: Narrower-than-Expected Net Loss Highlights Cost ManagementPositive Surprise Momentum - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com
MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks
Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies - Moomoo
MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada
MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan
Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan
MIRA Q3 2025 Earnings: Positive EPS Surprise Fails to Lift SharesEarnings Revision Report - DonanımHaber
Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News
Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo
0.44%
0.19%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):